Onyx
Pharmaceuticals, Inc. ONXX today announced an underwritten
public offering of 4,400,000 shares of its common stock. Onyx has
also granted the underwriters a 30-day option to purchase up to an
additional 660,000 shares of common stock offered in the public
offering to cover overallotments, if any. The offering is expected to
close on or about January 22, 2013, subject to customary closing
conditions. Onyx intends to use the net proceeds from this offering
to fund its clinical development programs, research and development
activities, and sales and marketing activities to commercialize
Kyprolis around the world, and for general corporate purposes,
including working capital.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in